NPORT-EX 2 NPORT_8292786960427300.htm iShares Global Healthcare ETF

Schedule of Investments  (unaudited) 

December 31, 2019

   

iShares® Global Healthcare ETF

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  

Common Stocks

    
Australia — 2.0%            

Cochlear Ltd.

     21,917     $ 3,462,316  

CSL Ltd.

     171,759       33,294,714  

Ramsay Health Care Ltd.

     61,201       3,120,331  

Sonic Healthcare Ltd.

     171,448       3,464,933  
   

 

 

  
      43,342,294  
Belgium — 0.4%            

Galapagos NV(a)(b)

     18,388       3,849,457  

UCB SA

     48,928       3,893,945  
   

 

 

  
      7,743,402  
Canada — 0.2%            

Bausch Health Companies Inc.(a)

     118,009       3,537,313  

Canopy Growth Corp.(a)

     83,812       1,765,110  
   

 

 

  
      5,302,423  
Denmark — 2.2%            

Coloplast A/S, Class B

     44,140       5,479,540  

Genmab A/S(a)

     24,565       5,466,884  

Novo Nordisk A/S, Class B

     626,712       36,400,510  
   

 

 

  
        47,346,934  
France — 2.1%            

Sanofi

     435,195       43,779,923  
   

 

 

  
Germany — 2.5%            

Bayer AG, Registered

     354,166       28,945,699  

Fresenius Medical Care AG & Co. KGaA

     80,121       5,932,164  

Fresenius SE & Co. KGaA

     156,293       8,803,520  

Merck KGaA

     49,522       5,856,240  

QIAGEN NV(a)

     86,382       2,953,516  
   

 

 

  
      52,491,139  
Ireland — 0.2%            

Steris PLC

     32,159       4,901,675  
   

 

 

  
Japan — 6.0%            

Astellas Pharma Inc.

     675,175       11,617,918  

Chugai Pharmaceutical Co. Ltd.

     80,500       7,466,667  

Daiichi Sankyo Co. Ltd.

     231,000       15,363,865  

Eisai Co. Ltd.

     113,800       8,590,892  

Hoya Corp.

     143,500       13,798,712  

M3 Inc.

     164,600       5,005,779  

Olympus Corp.

     493,700       7,672,963  

Ono Pharmaceutical Co. Ltd.

     193,400       4,452,604  

Otsuka Holdings Co. Ltd.

     209,500       9,413,283  

Shionogi & Co. Ltd.

     111,000       6,911,773  

Sysmex Corp.

     62,200       4,263,426  

Takeda Pharmaceutical Co. Ltd.

     596,692       23,785,321  

Terumo Corp.

     261,900       9,362,609  
   

 

 

  
      127,705,812  
Netherlands — 0.8%            

Koninklijke Philips NV

     343,042       16,758,006  
   

 

 

  
South Korea — 0.3%            

Celltrion Inc.(a)

     40,761       6,379,645  
   

 

 

  
Spain — 0.2%            

Grifols SA

     110,997       3,915,992  
   

 

 

  
Switzerland — 10.1%            

Alcon Inc.(a)

     184,863       10,461,602  

Lonza Group AG, Registered

     28,302       10,322,989  

Novartis AG, Registered

     966,669       91,740,467  
Security   Shares     Value  
Switzerland (continued)            

Roche Holding AG, Bearer

     10,317     $ 3,277,234  

Roche Holding AG, NVS

     266,490       86,412,826  

Sonova Holding AG, Registered

     20,890       4,778,370  

Straumann Holding AG, Registered

     4,225       4,146,682  

Vifor Pharma AG

     15,904       2,901,267  
   

 

 

  
      214,041,437  
United Kingdom — 4.8%            

AstraZeneca PLC

     497,849       50,170,129  

GlaxoSmithKline PLC

     1,890,663       44,557,851  

Smith & Nephew PLC

     335,462       8,143,695  
   

 

 

  
      102,871,675  
United States — 67.8%            

Abbott Laboratories

     668,902         58,100,827  

AbbVie Inc.

     561,499       49,715,122  

ABIOMED Inc.(a)

     17,226       2,938,583  

Agilent Technologies Inc.

     117,192       9,997,650  

Alexion Pharmaceuticals Inc.(a)(b)

     85,053       9,198,482  

Align Technology Inc.(a)(b)

     27,543       7,685,599  

Allergan PLC

     124,711       23,841,002  

AmerisourceBergen Corp.

     57,574       4,894,942  

Amgen Inc.

     225,381       54,332,598  

Anthem Inc.

     96,180       29,049,245  

Baxter International Inc.

     193,958       16,218,768  

Becton Dickinson and Co.

     102,405       27,851,088  

Biogen Inc.(a)

     68,444       20,309,388  

Boston Scientific Corp.(a)(b)

     529,637       23,950,185  

Bristol-Myers Squibb Co.

     890,180       57,140,654  

Cardinal Health Inc.

     112,886       5,709,774  

Centene Corp.(a)

     156,774       9,856,381  

Cerner Corp.

     120,959       8,877,181  

Cigna Corp.(a)

     141,645       28,964,986  

Cooper Companies Inc. (The)

     18,928       6,081,377  

CVS Health Corp.

     493,780       36,682,916  

Danaher Corp.

     242,333       37,193,269  

DaVita Inc.(a)

     33,194       2,490,546  

DENTSPLY SIRONA Inc.

     85,319       4,828,202  

Edwards Lifesciences Corp.(a)

     79,039       18,439,008  

Eli Lilly & Co.

     320,486       42,121,475  

Gilead Sciences Inc.

     480,829       31,244,268  

HCA Healthcare Inc.

     100,865       14,908,856  

Henry Schein Inc.(a)(b)

     56,618       3,777,553  

Hologic Inc.(a)

     101,864       5,318,319  

Humana Inc.

     50,231       18,410,666  

IDEXX Laboratories Inc.(a)(b)

     32,708       8,541,040  

Illumina Inc.(a)

     55,787       18,506,779  

Incyte Corp.(a)

     67,626       5,905,102  

Intuitive Surgical Inc.(a)

     43,703       25,835,029  

IQVIA Holdings Inc.(a)

     69,270       10,702,908  

Johnson & Johnson

     998,300       145,622,021  

Laboratory Corp. of America Holdings(a)

     37,447       6,334,909  

McKesson Corp.

     68,347       9,453,757  

Medtronic PLC

     509,363       57,787,232  

Merck & Co. Inc.

     965,722       87,832,416  

Mettler-Toledo International Inc.(a)

     9,211       7,306,902  

Mylan NV(a)

     194,679       3,913,048  

PerkinElmer Inc.(b)

     41,916       4,070,044  

Perrigo Co. PLC

     51,398       2,655,221  

Pfizer Inc.

     2,099,591       82,261,975  

Quest Diagnostics Inc.

     51,030       5,449,494  
 

 

 

1

Schedule of Investments  (unaudited) (continued)

December 31, 2019

   

iShares® Global Healthcare ETF

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  
United States (continued)            

Regeneron Pharmaceuticals Inc.(a)

     30,426     $ 11,424,355  

ResMed Inc.

     54,464       8,440,286  

Stryker Corp.

     121,811         25,573,001  

Teleflex Inc.

     17,476       6,578,665  

Thermo Fisher Scientific Inc.

     151,689       49,279,205  

UnitedHealth Group Inc.

     359,100       105,568,218  

Universal Health Services Inc., Class B(b)

     31,244       4,482,264  

Varian Medical Systems Inc.(a)(b)

     34,535       4,904,315  

Vertex Pharmaceuticals Inc.(a)

     96,851       21,205,527  

Waters Corp.(a)

     25,256       5,901,064  

WellCare Health Plans Inc.(a)

     19,048       6,289,840  

Zimmer Biomet Holdings Inc.

     77,769       11,640,464  

Zoetis Inc.

     181,334       23,999,555  
   

 

 

  
      1,437,593,546  
   

 

 

  

Total Common Stocks — 99.6%
(Cost: $1,705,275,714)

       2,114,173,903  
   

 

 

  

Short-Term Investments

    
Money Market Funds — 1.0%            

BlackRock Cash Funds: Institutional,
SL Agency Shares,
    1.84%(c)(d)(e)

     18,863,058       18,870,603  
Security   Shares     Value  
Money Market Funds (continued)            

BlackRock Cash Funds: Treasury,
SL Agency Shares,
    1.52%(c)(d)

     1,418,928     $ 1,418,928  
   

 

 

  
      20,289,531  
   

 

 

  

Total Short-Term Investments — 1.0%
(Cost: $20,289,174)

         20,289,531  
   

 

 

  

Total Investments in Securities — 100.6%
(Cost: $1,725,564,888)

       2,134,463,434  

Other Assets, Less Liabilities — (0.6)%

       (12,927,471 ) 
   

 

 

  

Net Assets — 100.0%

     $   2,121,535,963  
   

 

 

  

 

(a) 

Non-income producing security.

(b) 

All or a portion of this security is on loan.

(c) 

Affiliate of the Fund.

(d) 

Annualized 7-day yield as of period-end.

(e) 

All or a portion of this security was purchased with cash collateral received from loaned securities.

 

Affiliates

Investments in issuers considered to be affiliates of the Fund during the nine months ended December 31, 2019, for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

 

Affiliated Issuer   

Shares

Held at

03/31/19

      Net Activity     

Shares

Held at

12/31/19

     

Value at

12/31/19

      Income     

Net Realized

Gain (Loss)

     

Change in

Unrealized

Appreciation

(Depreciation)

  

BlackRock Cash Funds: Institutional,
SL Agency Shares

      —        18,863,058        18,863,058      $ 18,870,603      $ 362,444 (a)     $ 988      $ 357  

BlackRock Cash Funds: Treasury,
SL Agency Shares

      2,712,643        (1,293,715 )       1,418,928        1,418,928        46,204        —        —  
           

 

 

     

 

 

     

 

 

     

 

 

  
            $ 20,289,531      $ 408,648      $ 988      $ 357  
           

 

 

     

 

 

     

 

 

     

 

 

  

 

  (a) 

Includes securities lending income earned from the reinvestment of cash collateral from loaned securities (excluding collateral investment fees), net of fees and other payments to and from borrowers of securities, and less fees paid to BTC as securities lending agent.

 

Futures Contracts

 

Description    Number of
Contracts		       

Expiration

Date

       

Notional

Amount

(000)

       

Value/

Unrealized

Appreciation

(Depreciation)

  

Long Contracts

                  

E-Mini S&P Select Sector Health Care Index

      59          03/20/20        $ 6,086        $ 64,725  
                 

 

 

  

Fair Value Measurements

Various inputs are used in determining the fair value of financial instruments. For description of the input levels and information about the Fund’s policy regarding valuation of financial instruments, refer to a recently published shareholder report. Shareholder reports are available on the Fund’s website at iShares.com and on the U.S. Securities and Exchange Commission website at sec.gov.

 

 

2

Schedule of Investments  (unaudited) (continued)

December 31, 2019

   

iShares® Global Healthcare ETF

    

 

Fair Value Measurements (continued)

The following table summarizes the value of the Fund’s investments according to the fair value hierarchy as of December 31, 2019. The breakdown of the Fund’s investments into major categories is disclosed in the Schedule of Investments above.

 

                                                                                                   
      Level 1        Level 2        Level 3        Total  

Investments

                  

Assets

                  

Common Stocks

    $ 2,114,173,903        $ —        $ —        $ 2,114,173,903  

Money Market Funds

      20,289,531          —          —          20,289,531  
  

 

 

       

 

 

       

 

 

       

 

 

  
   $ 2,134,463,434        $ —        $ —        $ 2,134,463,434  
  

 

 

       

 

 

       

 

 

       

 

 

  

Derivative financial instruments(a)

                  

Assets

                  

Futures Contracts

    $ 64,725        $ —        $ —        $ 64,725  
  

 

 

       

 

 

       

 

 

       

 

 

  

 

  (a)

Shown at the unrealized appreciation (depreciation) on the contracts.

 

 

Portfolio Abbreviations — Equity
NVS    Non-Voting Shares

 

 

3